$UTMD

Utah Medical Products (UTMD) announced a self-tender offer to repurchase up to 650,000 shares, or 20% of its outstanding shares, at $75.00 per share. This price is 17% higher than the 12-month average and 21% higher than the 2-year average. The offer, starting September 22, is not conditioned on a minimum number of shares. The company's board approved the offer but did not recommend it to stockholders.

Utah Medical Products (Nasdaq: UTMD) said its board approved a quarterly cash dividend of $0.31 per share payable Oct. 5, 2026 to shareholders of record as of Sept. 17, 2026. The company stated this is a 1.6% increase versus the dividend declared for the same quarter a year earlier.

UTAH MEDICAL PRODUCTS INC (UTMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 utmd_ex99z1.htm EXHIBIT 99.1 EXHIBIT 99.1 UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2026 Contact: Brian Koopman (801) 566-1200 July 23, 2026 Salt Lake City, Utah – Utah Medical Products, Inc. [Nasdaq: UTMD] reports second calendar qua

Utah Medical's Q3 earnings fell 20% year over year as order cancellations and tariffs pressured margins. Growth in U.S. Filshie devices and direct sales helped partially offset declines.

Utah Medical's Q2 earnings decrease year over year on lower OEM sales and weak international demand, though cost controls helped cushion margins.

UTMD's Q1 2025 earnings fall 16% amid weak OEM sales, FX pressures and higher taxes, despite lower litigation costs and a strong cash position.